A baptism of fire for listing medtechs
Medtechs going public in 2020 raised a decent amount of cash, but have had a turbulent time of it since.
Medtech venture investors live up to their name
Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.
Biopharma takeovers show quantity, if not quality
Second-quarter deal values plummeted as Covid-19 spread and the prices of target companies spiralled.
Venture investors: biotech's preppers?
A handful of huge financings helped start-ups raise a record $5.4bn in the second quarter as investors brace for tougher times.
Biopharma shares shake off the pandemic
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
Smaller device makers put in a muted performance
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
What pandemic? Biotech floats break records
After a brief pause in the first quarter flotations have come flooding back, with drug developers raising almost $5bn so far this year.
Roche and Lilly most vested in research
The world’s largest drug companies splashed out a record $78bn on R&D last year, with Roche and Lilly the biggest spenders.
